Woburn Rehabilitation And Nursing Center
WOBURN REHABILITATION AND NURSING CENTER in WOBURN, MA — inspection on January 9, 2025.
Found 1 citation. Severity: Standard violations.
Health inspections identify deficiencies that facilities must correct within required timeframes. Violations range from minor documentation issues to serious safety concerns and are subject to follow-up verification.
Inspection Findings
According to the U.S.
Food and Drug Administration prescribing information for flecainide acetate (an antiarrhythmic medication used to prevent or treat irregular heartbeats), dated December 2024, indicated:
- Flecainide acetate should be used by prescription only.
- Flecainide acetate, like other antiarrhythmic agents, can cause new or worsened supraventricular or ventricular arrhythmias.
Ventricular proarrhythmic effects range from an increase in frequency of PVCs to the development of more severe ventricular tachycardia, e.g., tachycardia that is more sustained or more resistant to conversion to sinus rhythm, with potentially fatal consequences.
According to the U.S.
Food and Drug Administration prescribing information for escitalopram oxalate (an antidepressant medication), dated August 2023, indicated:
- Escitalopram oxalate should be used by prescription only.
225394
Form Approved OMB
STATEMENT OF DEFICIENCIES (X1) PROVIDER/SUPPLIER/CLIA (X2) MULTIPLE CONSTRUCTION (X3) DATE SURVEY AND PLAN OF CORRECTION IDENTIFICATION NUMBER: COMPLETED A.
Building 225394 B.
Wing 01/09/2025
NAME OF PROVIDER OR SUPPLIER STREET ADDRESS, CITY, STATE, ZIP CODE
Woburn Rehabilitation and Nursing Center 18 Frances Street, #3095 Woburn, MA 01801